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Abstract 
Background 
25-hydroxylase (CH25H) is an Interferon stimulated gene (ISG), which catalyzes the 
synthesis of 25-Hydroxycholesterol (25HC). 25HC intervenes in metabolic and infectious 
processes as controls cholesterol homeostasis and influences viral entry into host cells. 
We verified whether natural resistance to HIV-1 infection in HIV-1-exposed seronegative 
(HESN) individuals is at least partially mediated by particularities in sterol biosynthesis.  
 
Methods 
Peripheral blood mononuclear cells (PBMCs) and monocyte-derived macrophages (MDMs) 
isolated from 15 sexually-exposed HESN and 15 healthy controls (HC) were in vitro HIV-1-
infected and analyzed for: 1) percentage of IFN-producing plasmacytoid Dendritic Cells 
(pDCs); 2) Cholesterol signaling and inflammatory response RNA expression; 3) resistance 
to HIV-1 infection. MDMs from 5 HC were in vitro HIV-1-infected in the absence/presence 
of exogenously added 25HC. 
Results  
IFN-producing pDCs were augmented in HESN compared to HCs both in unstimulated and 
in in vitro HIV-1-infected PBMCs (p<0.001). An increased expression of CH25H and of a 
number of genes involved in cholesterol metabolism (ABCA1, ABCG1, CYP7B1, LXR, 
OSBP, PPARSCARB1) was observed as well; this, was associated with a reduced 
susceptibility to in vitro HIV-1-infection of PBMCs and MDMs (p<0.01). Notably, addition 
of 25HC to MDMs resulted in increased cholesterol efflux and augmented resistance to in 
vitro HIV-1-infection. 
 
  
Conclusions 
Results herein show that in HESN sterol metabolism might be particularly efficient. This 
could be related to the activation of the IFN pathway and results into a reduced 
susceptibility to in vitro HIV-1 infection. These results suggest a possible basis for 
therapeutic interventions to modulate HIV-1 infection. 
Keywords: Sterol metabolism, CH25H, HIV-1, HESN,immunity 
 
Introduction  
In the last decades several studies tried to explain the phenomenon of natural resistance to 
HIV-1infection displayed by different cohorts of individuals. These individuals, referred to as 
HIV-1–exposed seronegative (HESN) have the extraordinary capacity to remain HIV-1 
uninfected despite frequent risk behaviors, including injection drug use with needle sharing 
or sexual intercourse with infected partners [1,2]. Natural protection to HIV-1 infection has 
been associated with a wide range of genetic and immunological factors [3–5]. In particular, 
several publications reported a strong correlation between HIV-1 infection, resistance and the 
presence of an immune activation status [4,6,7]. Indeed, even if not all results are in 
agreement [8–11] HESNs have been convincingly shown to be characterized by an increased 
expression of activation markers on circulating cells and greater production of immunological 
effector molecules both in unstimulated condition and upon specific-stimulation [6,12–15].  
Among the different immunological factors thus  far correlated with the HESN phenotype, 
Type-I Interferons seem to play a crucial role in controlling HIV-1 infection [3,4,16–18]. 
Their mechanisms of action is mediated by the activation of the so called interferon 
stimulated genes (ISGs), a number of which can interfere with viral replication at different 
levels [19,20]. The ER-associated enzyme cholesterol-25-hydroxylase (CH25H) is one of 
these ISGs and it modulates viral replication through of its effect on cholesterol metabolism 
[21]. The regulation of the virus-cholesterol axis is indeed essential for the correct assembly 
and release of functional virions [22–24]. Both enveloped and naked viruses have to interact 
with the phospholipidic membrane in order to enter the cell and, once produced, new virions 
need to exit to spread to new targets. These steps require the virus to cross the plasma 
membrane of the cell twice: firstly, via fusion mediated by the envelope glycoprotein, to 
deliver the viral core into the cytosol; and secondly by the scission of budding virions during 
release. Once inside the cell, viruses can affect  lipid homeostasis and intracellular signaling 
in order to hijack the cell metabolism towards virus’ needs [25,26].  
To counteract such viral usurpation and restore a functional balance of cholesterol outflow, 
the infected cell can adopt different strategies. For example, the activation of liver X receptor 
(LXRs) and/or the inhibition of sterol regulatory element–binding protein (SREBPs) 
pathways result in restriction of viral replication, including HIV and HCV[25,27–30]. This 
makes sense considering the role played by these molecules in cholesterol metabolisms: 
SREBP1 provides a feedback regulatory system involved in biosynthesis and uptake of 
cholesterol [31] LXR, instead, favors the elimination of excess cholesterol [32] by positively 
regulating the expression of genes encoding lipid-transport proteins, such as ATP-binding 
cassette A1 (ABCA1), and ATP-binding cassette G1 (ABCG1) [33,34]. Notably, 25HC 
synthetized by CH25H acts exactly as a positive and negative regulator of LXR and SREPB2, 
respectively, thus impairing virus-cell fusion [21,35]. Actually, 25HC inhibits the growth of a 
wide range of enveloped viruses by inducing structural changes in the cellular membrane, 
thus preventing  viral entry at the virus-cell fusion step[36–38]. As confirmation, recent 
results obtained in a biomembrane model system, showed that liposome fusion is reduced by 
50% in the presence of 25HC, comparatively to cholesterol. Additional data indicated that 
25HC affects the membrane fusion process through the modification of lipid membrane 
properties, and by direct alterations on HIV-fusion peptide structure, suggesting the 
possibility to employ 25HC as antiviral molecule [39,40]. 
Furthermore, a study performed in our laboratory has shown that Tiazolides (TZD), a class of 
drugs with a known in vitro and in vivo activity against a wide range of pathogens, reduce 
HIV-1-infection (>90%) through the modulation of CH25H as well [37] These findings lead 
us to speculate on the possibility that the massive efflux of cholesterol from cells could 
deprive the virus of components necessary for the assembly of new virions and interfere with 
the budding process, limiting a strong virus spread [37]. 
As any determinant involved in the HIV-1 resistance processes could potentially be exploited 
in the development of novel preventative and therapeutic strategies, the analysis of 
immunologic correlates of the HESN phenotype is still a fascinating and prolific branch in 
HIV research. Based on these observations, we decided to verify whether the natural 
resistance to HIV-1 infection seen in HESN is at least partially dependent on a peculiar 
regulation of the sterol biosynthesis pathway mediated by IFN-induced CH25H expression. 
 
Materials and methods 
Study population 
We recruited 15 HESN exposed to HIV-1 infection by unprotected heterosexual intercourse 
from an Italian cohort (Santa Maria Annunziata hospital, Florence, Italy) whose 
epidemiological and clinical characteristics as well as inclusion criteria were previously 
described [6]. A group of 15 HIV-1 seronegative healthy blood donors (HC) from the same 
hospital was used as controls. Notably, none of the subjects included in the study were 
receiving anticholesterol medications before or at the time of this study. 
The study was designed and performed according to the Helsinki declaration and was 
approved by the Ethics Committee of the participating units. All subjects provided written 
informed consent to participate in this study. 
 
PBMC isolation and monocyte derived macrophages (MDMs) differentiation. 
Peripheral blood mononuclear cells (PBMCs) from all the subjects enrolled in the study were 
separated as previously described [41]. Number of viable leukocytes was determined by an 
automatic cell counter (Digital Bio, NanoEnTek Inc, Korea).  
After determining the percentage of monocytes at flow cytometer, 500,000 monocyte/well 
were differentiated in MDMs as previously reported [42].  
 
In vitro HIV-1 infection of PBMCs and MDMs from HESN and HC 
2x10
6
 PBMCs isolated from 15 HESN and 15 HC were cultured in RPMI 1640 containing 
20% fetal bovine serum, with or without 0.5 ng/1x10
6
 cells HIV-1Ba-L virus with a cellular 
density of 2x10
6
 /ml and incubated for 24 h at 37°C and 5% CO2. Cells were then washed and 
resuspended in medium containing IL-2 (15 ng/ml) (R&D Systems, Minneapolis, Minnesota, 
USA). Three and 7 days post in vitro HIV-1 infection 1x10
6
 PBMCs were used to determine 
IFN-alpha-producing pDC percentage and mRNA expression genes, respectively. p24 ELISA 
was performed on 7 days post-infection supernatants.   
MDMs from 10 HESN and 10 HC subjects were cultured in RPMI 1640 containing 20% FBS 
and 0.5ng/1 x10
6
 cells HIV-1Ba-L and incubated for 24 h at 37°C and 5% CO2. At the end of 
incubation, the attached macrophages were washed with PBS and cultured in complete 
medium containing 20% FBS for 7 days. Half of the medium was changed 3 and 5 days post 
infection. Seven days post infection supernatant was collected for p24 antigen ELISA 
quantification. 
MDMs differentiated from 5 HC were overnight pretreated with 25HC (1M) (Cayman 
Chemical, Ann Arbor, Michigan, USA). In vitro HIV-1-infection was performed as 
previously described. 25HC was administered just once at the start of our cell culture 
experiments. Four and 7 days post in vitro HIV-1 infection RNA expression and p24 antigen 
ELISA quantification were assessed, respectively. 
 
p24 ELISA  
An HIV-1 p24 Elisa assay kit (XpressBio, Frederick, Maryland, USA) was used to measure 
viral p24 antigen in supernatant of PBMCs, MDMs and 25HC treated MDMs differentiated 
from monocytes of HESN and HC after 7 days HIV-1 infection, according to the 
manufacturer’s protocol.  
 
Flow cytometry 
Flow cytometric analyses were performed on uninfected and 3 days post infection to pDCs 
characterization. 0.5X10
6
 PBMCs were stained after with anti-human LIN- labeled with 
FITC (eBioscience, MA, USA), anti-human CD123 labeled with PE and anti-human HLADR 
labeled with PC7 followed by fixation, permeabilization and incubation with anti-human 
IFN labeled with APC (Biolegend, San Diego, California, USA). At least 200 000 events 
were acquired in the gate of LIN-cells, using a Gallios flow cytometer (Beckman-Coulter, 
San Jose, California, USA). In order to calculate the percentage of monocytes in isolated 
PBMCs, 250,000 cells were resuspended in PBS, and stained for surface antibodies: CD36 
FITC, CD4 PC5, CD14 PC7 (Beckman-coulter, Fullerton, CA).  
 
RNA extraction and Retro-transcription (RT) 
RNA was extracted from 1 × 106 PBMCs and 5x105 MDMs by using the acid guanidium 
thiocyanate–phenol–chloroform method. RNA was dissolved in RNase-free water, and 
purified from genomic DNA with RNase-free DNase (RQ1 DNase, Promega, Madison, 
Wisconsin, USA). One microgram of RNA was reverse transcribed into first-strand cDNA in 
a 20-μl final volume containing 1 μM random hexanucleotide primers, 1 μM oligo dT and 
200 U Moloney murine leukemia virus reverse transcriptase (Clontech, Palo Alto, California, 
USA). 
 
Cholesterol signaling and inflammatory response gene expression  
Cholesterol signaling and inflammatory response gene expression by unstimulated and 7-days 
in vitro HIV-1-infected PBMCs was analyzed in a custom PCR array including a set of 48 
optimized real-time PCR primer assays (SABiosciences Corporation, Frederick, MD, USA). 
Only targets showing >2-fold modulation were considered significant. Experiments were run 
on all the subjects included in the study pooled into two distinct groups (HESN and HC) and 
represent the mean value of the different targets analyzed in each group. Reactions were 
performed using a SYBR Green PCR mix (Bio-rad, CA, USA) using CFX manager 3.1 
thermal cycler (Bio Rad) as previously described [41]. 
To validate the results obtained by array analyses, some selected significant targets were 
quantified by individual real-time PCR on cDNA obtained from in vitro HIV-1-infected 
MDMs differentiated from 10 HESN and 10 HC subjects. The same targets were analyzed on 
cDNA obtained from in vitro HIV-1-infected MDMs of 5 HC treated or untreated with 
25HC. 
 
Statistical analysis 
Data were analyzed using Student’s T or ANOVA test by GRAPHPAD PRISM version 5 
(Graphpad software, La Jolla, Ca, USA), and p-values of 0.05 or less were considered to be 
significant. 
 
Results 
Susceptibility of PBMCs and MDMs from HESN to HIV-1 infection in vitro 
To confirm that HESN subjects are less susceptible to HIV-1 infection, PBMCs and MDMs 
isolated from   HESN and  HC were in-vitro infected with HIV-1 Bal. Results showed that 
seven days after in vitro HIV-1-infection p24 levels in PBMC cultures were significantly 
lower in HESN (mean: 57640 +/- 19590 pg/ml) compared with HC (mean value: 120234+/-
32503 pg/ml) (p<0.01) (Fig. 1A). Likewise, 7 days post in vitro HIV-1-infection, virus-
replication was reduced in MDMs from HESN (mean value: 68508+/-16251 pg/ml) 
compared to HC (mean value: 104381+/-15248 pg/ml) (p<0.02) (Fig. 1B). 
 
IFNα-producing plasmacytoid dendritic cells (pDCs) in uninfected and in vitro HIV-1-
infected PBMCs of HESN and HC   
To verify whether resistance to in vitro HIV-1 infection is mediated by increased production 
of Type-I interferons we decide to analyze the percentage of plasmacytoid dendritic cells 
(pDCs) in PBMCs isolated from HESN and HC. Interestingly, the percentage of IFN- 
producing pDCs was significantly higher in unstimulated PBMCs isolated from HESN 
compared to HC (p<0.001). Such differences became even more evident analyzing 3 days 
post in vitro HIV-1 infection PBMCs isolated from HESN compared to HC (p<0.0002) 
(Figure 2). This result suggests a key role for this cellular subset in mediating antiviral 
immune response. 
 
Modulation of Cholesterol signaling and inflammatory response gene expression in 
uninfected and in vitro HIV-1-infected PBMCs and MDMs of HESN 
Since Type1 Interferon expression by pDCs is increased in HESN and CH25H is an ISGs 
involved in cholesterol metabolism, we verified whether natural resistance to HIV-1 infection 
is also dependent on this pathway.  
Results obtained in uninfected PBMCs from HESN and HC showed an up-regulation of 
genes involved in cholesterol metabolism and efflux (CH25H, CYP7B1, INSIG1, LXR, 
LXR, MBTPS1, PPAR, RXR RXR), as well as of different membrane receptors and 
cholesterol transporters (ABCA1, ABCG1, CD36, LDLR, MSR1, SCARB1) in PBMCs from 
HESN compared to HC (Figure 3). Even the expression of different modulators involved in 
the inflammatory response (CD80, CD86, IFN2, IFNR1, IFNR2, IFN, IL1) and 
antiviral response (IFITM3, OAS1) was increased in uninfected PBMCs from HESN 
compared to HC, suggesting a correlation between immune activation and the modulation of 
cholesterol metabolism (Figure 3). 
Notably, these differences were even more pronounced upon 7-days post in vitro HIV-1 
infection, as an up-regulation of the expression of enzymes (ACAT, CH25H, CYP7B1, 
INSIG1) transcription factors (LXRα, LXRβ, MBTPS1, PPARγ, RXRα, RXRβ) and 
membrane receptors (ABCA1, ABCG1, LDLR, MSR1, SCARB1) involved in cholesterol 
metabolism and efflux (Figure 3) was seen in PBMCs from HESN. CH25H, CYP7B1, LXRα 
and PPAR expression, in particular, was robustly (>12 fold) up-regulated in in vitro HIV-1-
infected PBMCs from HESN. Finally, the expression of mediators of the inflammatory 
(CD80 CD86, IFN2, IFNR1, IFNR2, IFN1, IL1, IL6, NFKBIA), and antiviral 
response (IFITM1, IFITM3, OAS1) was significantly increased as well in these cells (Figure 
3). 
To validate the involvement of cholesterol metabolism gene expression in natural resistance 
to HIV-1 infection, mRNA expression of some selected targets, whose expression was 
increased in PBMCs, was further investigated in 7-days in vitro HIV-1-infected MDMs from 
HESN and HC by QPCR. Results confirmed the trend previously observed in PBMCs. Thus, 
the expression of IFN was increased in in vitro HIV-1-infected MDMs from HESN 
compared to HC, though these differences did not reach statistical significance. Furthermore, 
the expression of ABCA1 (p<0.02), ABCG1 (p<0.02), CH25H (p<0.03), CYP7B1 (p<0.01), 
LXR (p<0.009), OSBP (p<0.02), PPAR (p<0.01) and SCARB1 (p<0.02) was significantly 
increased in in vitro HIV-1 infected MDMs from HESN compared to HC, while the 
expression of HMGCS1 and SREBP1 showed a trend of reduction in HESNs MDMs, 
although these differences were not statistically significant (Figure 4). 
 
Role of 25HC in MDM resistance to in vitro HIV-1-infection 
To further confirm the protective role exerted by 25HC in resistance to HIV-1-infection, 
MDMs of 5 HC were in vitro HIV-1-infected the presence/absence of 25HC. Results showed 
that incubation of cells with 25HC reduced HIV-1-replication by nearly 60% (p<0.001) 
(Figure 5A). Such control of HIV-1-replication was associated with a significant increase in 
the expression of IFN mRNA (p<0.03) and of nuclear transcription factor LXR (p<0.03) 
which, in turn, upregulated the expression of the two main factors responsible for cholesterol 
efflux: ABCA1 and ABCG1 (p<0.02 for both) (Figure 5B). 
Discussion 
The main findings of this study shed new light on a molecule whose involvement in HIV 
replication has been widely demonstrated: cholesterol. Indeed, it is documented that HIV 
entry, assembly, budding and release mainly take place in specialized cholesterol-enriched 
microdomains, called lipid rafts, in the plasma membrane [43]. It is also important to 
underline that following long-term antiretroviral therapy HIV-patients display an altered lipid 
profile which can result in dyslipidemia [44], and that disease progression was shown to be 
delayed in HIV-infected patients showing increased cholesterol metabolism and reduced 
cholesterol synthesis [45–47]. Further, corroborating the link between HIV-infection and 
cholesterol metabolism our results show that cells isolated from subjects who naturally resist 
to HIV-infection (HESN) manifest an alteration of several factors involved in different steps 
of cholesterol metabolism including synthesis, efflux and uptake, both in uninfected and in in 
vitro HIV-infected conditions. HESN subjects are, basically, more prone to release 
cholesterol in the extracellular milieu and to reduce its synthesis, thus favoring HIV 
replication, a cholesterol-dependent process.  
The triggering factors responsible for cholesterol pathway alteration in HESN seem to be 
type I interferons (IFNs), mainly produced by plasmacytoid DCs (pDCs), whose percentage 
was significantly augmented in uninfected as well as in vitro HIV-1-infected PBMCs from 
HESN. IFNs are considered one of the most potent anti-viral signaling molecules; their effect 
being mediated by the upregulation of several ISGs [3,4,21] among which, CH25H is 
suggested to play a pivotal role. The expression of this enzyme, which catalyzes the 
formation of 25HC from cholesterol [48] was, indeed, significantly augmented in both 
uninfected and in vitro HIV-1-infected PBMCs and MDMs from HESN and is likely to be at 
least in part responsible for the 25HC-dependent upregulation of LXR and downregulation 
of SREBP1 [21,35], as we observed in our experimental setting. LXR, in particular, 
behaves as an oxysterol sensor of intracellular cholesterol homeostasis [21] and, when being 
produced in great abundance, blocks new cholesterol biosynthesis while promoting its efflux 
[21]. The activation of such strategy is corroborated by the observation that, among others, 
the expression of ABCA1 and ABCG1, two transmembrane proteins responsible for 
cholesterol efflux from cells, is significantly augmented, while the expression of HMGCS1, a 
key enzyme of cholesterol synthesis, is reduced in cells from HESN compared to HC. Other 
genes whose expression was raised in HESN MDMs include: oxysterol-binding protein 
(OSBP), which endorses the mobilization of lipids from endoplasmic reticulum to Golgi, 
together with the downregulation of newly synthetized cholesterol [49] and peroxisome 
proliferated factor (PPAR) γ, that manages the removal of intracellular cholesterol [50]. 
Notably, the peculiar expression of these genes seen in HESN cells was greatly enhanced 
following in vitro HIV-1-infection, suggesting that cells of these individuals are programmed 
to set up an antiviral defensive strategy mediated by the modulation of the cholesterol 
metabolism.  
To further validate these findings MDMs from 5 HCs were in vitro HIV-1-infected after 
being pre-incubated with 25HC. Of note, HIV-1 replication in 25HC-treated MDMs was 
significantly reduced and was associated with a significant increase in mRNA expression of 
type I IFNs, LXR as well as of factors favoring cholesterol release such as ABCG1 and 
ABCA1. The ability of exogenous 25HC to control virus replication has already been 
demonstrated for different virus and cellular types [38,51–54], including HIV [21], but, to our 
knowledge, this is the first time that such protective effect has been documented in human 
MDMs. 
Another aspect that should be considered concerns the state of immune activation observed in 
HESN PBMCs both in uninfected and in in vitro HIV-1-infected condition. For example, it 
was recently reported that cholesterol efflux activation results in the suppression of the 
inflammasome assembly [55], and that inhibition of the NLRP3 inflammasome decreases 
foam cell formation of THP-1 macrophages by stimulating cholesterol efflux [56]. 
Nevertheless, 25HC has been also described as an amplifier of inflammatory signaling [57] 
and, even more important, persistent activation of the immune system was reported in 
patients with hypercholesterolemia, even when cholesterolemia is lowered by statins [58]. 
This condition was ascribed to the ability of monocytes to retain a long-term pro-
inflammatory phenotype after a brief exposure to a triggering factor, a phenomenon defined 
'trained immunity'. It’s, therefore, tempting to speculate that regardless of cholesterol 
reduction, monocytes from HESN are more prone to develop a trained immunity phenotype 
which can shield them from HIV-exposure through the release of pro-inflammatory 
cytokines. Further analyses are required to shed light on the role of this intriguing mechanism 
in natural resistance to HIV-infection. 
The analyses performed in this study do not allow to exclude that the modulation of 
cholesterol content seen in HESN cells is, as has been previously suggested, at least in part 
the result of genetic or epigenetic regulation of one or more factors [59,60]. Thus, ABCA1 
mRNA expression was shown to be increased in HIV-infected non progressors (NPs) as an 
inherited trait [45]. Additionally, two GWASs for HIV-1 infection susceptibility suggested a 
role of variants within or in proximity of the CYP7B1 gene in this phenomenon [61,62]. 
The CYP7B1 gene encodes an enzyme that is involved in cholesterol catabolism by 
inactivation of oxysterols [63] but it also controls numerous immune functions, via its 
catabolite 25HC [64]. Notably, one of such effect is IgA synthesis [65], a class of antibodies 
previously associated with resistance to HIV-1-infection [66,67]. However, comparisons of 
allelic and genotypic frequencies among three different HESN cohorts indicate that the two 
GWAS-defined variants in the CYP7B1 region do not strongly influence HIV-1 infection 
susceptibility [68]. We can, therefore, presume that the increased expression of CYP7B1 we 
observed in cells of our HESN upon in vitro HIV-1 infection is not genetically determined. 
Further studies will nevertheless be necessary to verify whether the peculiarities of 
cholesterol metabolism seen in HESN are genetically driven or secondary to environmental 
setting. 
This is not the first report trying to establish a correlation between natural resistance to HIV-
infection and cholesterol metabolism. In 2013, a study investigating nutritional status and 
metabolic disorders in a cohort of prepubertal HESN children showed a higher prevalence of 
dyslipidemia and hypercholesterolemia [69]. The authors concluded that intrauterine HIV-
exposure could be responsible for these differences, suggesting that even in the absence of 
productive infection, HIV is able to disrupt this pathway. More recently, Tort and colleagues 
explored cholesterol efflux in HIV-patients as well as in sexually-exposed HESN [70]. 
Results showed that low cholesterol efflux in HIV-patients was associated with reduced 
CD4+T-cells as well as with higher viral loads but, contrarily to our findings, a lower 
cholesterol efflux was seen in HESN compared to HC. Differences in the methods used to 
investigate the same mechanism could justify this discrepancy. Thus, whereas an assay on 
THP-1 cellular line using ApoB-depleted plasma from HESN as cholesterol acceptor was 
used by Tort, we analyzed the expression of determinants involved in cholesterol homeostasis 
on primary cells.  
Results herein are only the first step in understanding the mechanisms that operate in the 
ability of some individuals to spontaneously control HIV-1 infection. It is likely that several 
mechanisms that involve numerous molecular players are responsible for this phenomenon, 
and innovative approaches are needed to identify the contribution of cholesterol metabolism 
to each mechanism. Although preliminary, though, these results suggest the possibility that 
modulation of cholesterol metabolism could have a role in preventing or controlling HIV-1 
infection. 
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Figure 1. Susceptibility to in vitro HIV-1 infection was reduced in peripheral blood 
mononuclear cells (PBMCs) and human monocyte derived macrophages (MDMs). (A) 
PBMCs from 15 HESN (gray bar) and 15 HC (white bars) were in vitro HIV-1-infected with 
a R5 HIV1Ba-L. (B) MDMs from from 10 HESN (gray bar) and 10 HC (white bars) were in 
vitro infected with a R5 HIV1Ba-L. P24 concentration was measured by ELISA in 7 days 
post in vitro HIV-1 infection supernatants in all the experiments. Mean values +/- SEM are 
shown. *p < 0.05. 
 
Figure 2.The percentage of IFNa producing plasmacytoid dendritic cells (pDCs) was 
increased in HESN compered to HC in both uninfected and HIV-1-infected PBMCs. (A) 
Percentage of IFNa producing pDC  from 15 HESN (gray bars) and 15 HC (white bars) in 
uninfected and HIV-1 infected condition. Mean values +/- SEM are shown. 
**
p < 0.001, 
***
p 
< 0.001 
 
Figure 3. mRNA expression of 43 genes that are part of cholesterol signaling and 
inflammatory response was significantly altered in uninfected and HIV-infected PBMCs 
from HESN. Real-time PCR Array was performed on uninfected and in vitro HIV-1-infected 
peripheral blood mononuclear cells (PBMCs) from 15 HESN and 15 HC. Samples were 
pooled into two distinct groups (HESN and HC). Gene expression (nfold) is shown as a color 
scale from green to red (MEV multiple experiment viewer software). The Nfold of HESN vs 
HC untreated and HIV-infected are shown. Only targets showing at least >2-fold modulation 
are shown in table. 
 
  
Figure 4. mRNA expression of genes involved in cholesterol metabolismand and efflux  
was significantly altered in HIV-1-infected MDMs from HESN. mRNA expression of 
genes involved in cholesterol metabolism and efflux was evaluated by Real time PCR in 7-
days in vitro HIV-1-infected MDMS from 10 HESN (grey bars) and 10 HC (white bars). 
Mean values +/- SE are shown. 
*
p < 0.05. . 
**
p < 0.01. 
 
  
Figure 5. p24 viral antigen concentration and mRNA expression of genes involved in 
cholesterol metabolism and efflux  were significantly different in in vitro HIV-1-infected 
MDMs treated with 25hydroxy chlesterol (25HC) (A) MDMs from 5 HC were in vitro 
HIV-1-infected with a R5 HIV1Ba-L with (dark gray bars) or without 25HC (light gray bars) 
and p24 viral antigen was measured by ELISA 7days post infection. (B) mRNA expression 
analyses of genes involved in cholesterol metabolism and efflux was higher in MDMs from 
25HC-treated (dark gray bars ) compared to untreated (light gray bars) MDMs 7-days post in 
vitro HIV-1-infection. Mean values +/- SEM are shown. *p < 0.05. 
 
 
